These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23297496)

  • 1. [Factors influencing finasteride medication compliance in outpatients with benign prostatic hyperplasia].
    Lin YH; Wang JS; Jiang YG; Luo Y
    Zhonghua Nan Ke Xue; 2012 Oct; 18(10):891-5. PubMed ID: 23297496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride adherence-associated factors in Chinese benign prostatic hyperplasia patients.
    Lin YH; Jiang YG; Wang JS; Luo Y
    Urol Int; 2012; 88(2):177-82. PubMed ID: 22179115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.
    Nichol MB; Knight TK; Wu J; Barron R; Penson DF
    J Urol; 2009 May; 181(5):2214-21; discussion 2221-2. PubMed ID: 19296986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.
    Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J
    Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.
    Naslund M; Black L; Eaddy M; Batiste LR
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S17-22. PubMed ID: 17295601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2002; (1):19-22. PubMed ID: 11877966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Finasteride: an effective therapeutic for benign prostatic hyperplasia related gross hematuria in patients receiving anticoagulant].
    Lin YH; Jiang YG; Li MC; Peng T
    Zhonghua Nan Ke Xue; 2009 Jan; 15(1):31-3. PubMed ID: 19288745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns in alpha-blocker therapy for benign prostatic hyperplasia.
    Schoenfeld MJ; Shortridge EF; Gelwicks SC; Cui Z; Wong DG
    Am J Mens Health; 2014 May; 8(3):267-72. PubMed ID: 24262787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM; Runken MC; Grogg AL; Shah MB
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period.
    Naslund MJ; Carlson AM; Williams MJ
    J Urol; 2005 Jun; 173(6):2090-3; discussion 2093. PubMed ID: 15879849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L; Manieri C; Paradiso Galatioto G; Vicentini C
    Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report.
    Puchner PJ; Miller MI
    J Urol; 1995 Nov; 154(5):1779-82. PubMed ID: 7563345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
    Issa MM; Lin PJ; Eaddy MT; Shah MB; Davis EA
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.